Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03302416 · ClinicalTrials.gov registry record · Early Phase 1
CRF - Nociceptin Receptor Interactions
A Early Phase 1 study of Healthy, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT03302416: Completed Early Phase 1 study of Healthy, sponsored by University of Pittsburgh.
NCT03302416 is a Early Phase 1 study of Healthy that has completed, run by University of Pittsburgh. The registered enrollment target is 19 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03302416, a Early Phase 1 study of Healthy, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine if \[C-11\]NOP-1A receptor binding (VT) can be altered by an intravenous hydrocortisone (cortisol) challenge through CRF-NOP interactions
Primary Outcome
VT is the volume of distribution expressed relative to total plasma concentration. This is defined consistent with that reported in Consensus nomenclature for in vivo imaging of reversibly binding radioligands (Reference: J Cereb Blood Flow Metab 2007 Sep;27(9):1533-9. doi: 10.1038/sj.jcbfm.9600493)
Conditions Studied
Interventions
- DRUG Hydrocortisone
- RADIATION [C-11]NOP-1A
Study Locations (1)
Pennsylvania
- University of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2016-06-01 |
| Est. Completion | 2019-06-01 |
| Phase | Early Phase 1 |
What the finished NCT03302416 record still lists
NCT03302416 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Hydrocortisone is the first listed.
NCT03302416 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03302416 about?
NCT03302416 is a clinical study titled "CRF - Nociceptin Receptor Interactions". To determine if \[C-11\]NOP-1A receptor binding (VT) can be altered by an intravenous hydrocortisone (cortisol) challenge through CRF-NOP interactions
What is the current status of trial NCT03302416?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 19 participants. The study started on 2016-06-01. Estimated completion is 2019-06-01.
What conditions does trial NCT03302416 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT03302416?
The interventions under investigation include: Hydrocortisone (DRUG), [C-11]NOP-1A (RADIATION).
Who is sponsoring clinical trial NCT03302416?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03302416 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03302416's enrollment target sits among peer trials
19 898th of 1090 higher than 188 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mapping Auricular Vagus Nerve Circuitry
RECRUITING · Early Phase 1
-
Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function
RECRUITING · Early Phase 1
-
SV2A Density Cannabis Use Disorder
RECRUITING · Early Phase 1
-
CBD-Microglia PET Study
RECRUITING · Early Phase 1
-
Sex Disparities in Hypoxic Vasodilation and Impact of Obesity
RECRUITING · Early Phase 1
-
Positron Emission Tomography (PET) Contrast Agent Kinetics and Safety: [18F]-Fluoromannitol
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI